Onconova Therapeutics Inc (NASDAQ:ONTX) has received an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Brokers have set a twelve-month consensus price objective of $5.67 for the company and are predicting that the company will post ($0.72) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Onconova Therapeutics an industry rank of 103 out of 265 based on the ratings given to its competitors.

Several equities analysts have issued reports on the stock. Maxim Group set a $6.00 price objective on shares of Onconova Therapeutics and gave the company a “buy” rating in a report on Thursday, November 9th. HC Wainwright reissued a “buy” rating on shares of Onconova Therapeutics in a research note on Thursday, November 9th. Finally, ValuEngine raised shares of Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.

Shares of Onconova Therapeutics (NASDAQ:ONTX) opened at $1.54 on Monday. Onconova Therapeutics has a 52-week low of $1.46 and a 52-week high of $3.88.

Onconova Therapeutics (NASDAQ:ONTX) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.02. The business had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.29 million. Onconova Therapeutics had a negative net margin of 2,855.94% and a negative return on equity of 558.97%. sell-side analysts forecast that Onconova Therapeutics will post -2.82 earnings per share for the current year.

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Onconova Therapeutics by 58.4% in the second quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock worth $190,000 after buying an additional 32,418 shares in the last quarter. Sabby Management LLC lifted its stake in shares of Onconova Therapeutics by 104.0% in the second quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock worth $1,693,000 after buying an additional 399,640 shares in the last quarter. Finally, Tyndall Capital Partners L P lifted its stake in shares of Onconova Therapeutics by 91.4% in the second quarter. Tyndall Capital Partners L P now owns 997,022 shares of the biopharmaceutical company’s stock worth $2,154,000 after buying an additional 476,190 shares in the last quarter. 25.44% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/12/04/onconova-therapeutics-inc-ontx-given-5-67-average-target-price-by-analysts.html.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Get a free copy of the Zacks research report on Onconova Therapeutics (ONTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Onconova Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.